Media headlines about AveXis (NASDAQ:AVXS) have trended somewhat positive on Wednesday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AveXis earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.6026046150179 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several brokerages recently weighed in on AVXS. Royal Bank of Canada reaffirmed a “hold” rating and set a $92.00 price target on shares of AveXis in a report on Thursday, November 2nd. Wells Fargo & Company reaffirmed an “outperform” rating and set a $134.00 price target (up from $89.00) on shares of AveXis in a report on Tuesday, September 5th. BMO Capital Markets reaffirmed an “outperform” rating and set a $123.00 price target on shares of AveXis in a report on Saturday, September 30th. UBS reaffirmed a “buy” rating and set a $122.00 price target (up from $95.00) on shares of AveXis in a report on Tuesday, October 3rd. Finally, Citigroup increased their price target on AveXis from $100.00 to $116.00 and gave the stock a “buy” rating in a report on Monday, October 2nd. Four research analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the company’s stock. AveXis has an average rating of “Hold” and an average price target of $110.67.

AveXis (AVXS) traded down $1.06 during trading on Wednesday, reaching $104.43. The company’s stock had a trading volume of 252,228 shares, compared to its average volume of 428,312. AveXis has a 12 month low of $45.33 and a 12 month high of $108.27.

AveXis (NASDAQ:AVXS) last released its earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.04). During the same quarter in the prior year, the business earned ($0.87) earnings per share. equities research analysts expect that AveXis will post -6.19 EPS for the current year.

In other AveXis news, insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $94.73, for a total value of $1,420,950.00. Following the completion of the sale, the insider now owns 1,826,502 shares of the company’s stock, valued at $173,024,534.46. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $101.26, for a total value of $180,242.80. Following the completion of the sale, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $180,242.80. The disclosure for this sale can be found here. In the last three months, insiders sold 52,340 shares of company stock valued at $5,172,298. 18.60% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-avexis-avxs-stock-price/1775205.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Insider Buying and Selling by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.